Search Results 521-530 of 7893 for SC

  1. Publications - Julie K. Heimbach, M.D. - Mayo Clinic

    ... SC, Kirimker EO, Akamatsu N, Shaked O, Finotti M, Yeow M, Genedy L, Dutkowski P, Nadalin S, Boehnert MU, Polak WG, Bonney GK, Mathur A, Samstein B, Emond JC ...

  2. SCD1 is a Novel Molecular Target in Human Carcinomas - Cancer Biology and Translational Research - Mayo Clinic Research

    The Copland Cancer Biology and Translational Research Lab at Mayo Clinic has created novel SCD1-specific inhibitors that are being developed for cancer ...

  3. Publications

    ... SC, Lerman LO. Renal fibrosis detected by diffusion-weighted magnetic resonance imaging remains unchanged despite treatment in subjects with renovascular ...

  4. Center for Clinical and Translational Science (CCaTS)

    Michael Camilleri, M.D., D.Sc. —. Contact — Enteric Physiology and Imaging Facility · Irene A. Busciglio · 507-266-6615. Director — Muscle Performance and ...

  5. Alumni - Cerebrovascular and Skull Base Fellowship (Arizona) - Mayo Clinic College of Medicine and Science

    National Institute of Mental Health and Neurosciences, Bangalore, India. Current location: Medical University of South Carolina. Show more. Graduation of Mayo ...

  6. Mantle Cell Lymphoma Clinical Trials - Mayo Clinic Research

    The purpose of this study is to evaluate the effectiveness, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with ...

  7. Publications - Timothy B. Curry, M.D., Ph.D. - Mayo Clinic

    ... SC, Buckles S, Bumgardner M, Gallagher C, Fee-Schroeder K, Nicholas NR, Powers ML, Ragab AK, Richardson DM, Stai A, Wilson J, Pacyna JE, Olson JE, Sutton EJ ...

  8. Pyloric stenosis - Symptoms and causes - Mayo Clinic

    In this condition, a valve between an infant's stomach and small intestine fails to open enough for food to pass through. Surgery is the treatment.

  9. Lupus Clinical Trials - Mayo Clinic Research

    The purpose of this trial is to evaluate the effectiveness, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 ...

  10. Publications - Diva R. Salomao, M.D. - Mayo Clinic

    Balasubramaniam SC, Salomao DR, Davies JB, Ramsay RC, Habermann TM, Chow GK, Boorjian SA, Pulido JS. Paraneoplastic sarcoid-like reactions and the eye ...